EPHA3 and neoplasm: A 3-h treatment with EphB2-Fc or EphB4-Fc, but not with EphrinB1-Fc or EphrinB2-Fc, produces roundness and decreased size of Stro-1+ BM-MSC [6], and EphA3+ CD29+ Sca-1hi MSC isolated from tumor niche respond to an EphA3-activating monoclonal antibody (mAb) by fast contraction and apoptosis [20].